A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : NRI / norepinephrine reuptake inhibitor

[Related PubMed/MEDLINE]
Total Number of Papers: 76
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   NRI  (>> Co-occurring Abbreviation)
Long Form:   norepinephrine reuptake inhibitor
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Efficacy and tolerability of tapentadol prolonged release in the elderly and fragile patient: an observational study. MOR
2019 Efficacy of tapentadol prolonged release for pre- and post-operative low back pain: a prospective observational study. LBP, NRS, PR
2019 Pharmacological rationale for tapentadol therapy: a review of new evidence. MOR
2019 Tapentadol in an Experimental Animal Model of Acute Orofacial Pain. ---
2019 Tapentadol prolonged release and the long-term management of chronic musculoskeletal pain in the elderly - focus on anxiety, depression, cognitive status and life quality: the TaPE study. MOR, NRS, PR
2019 Tapentadol prolonged release in association with analgesic radiofrequency for the treatment of chronic lumbar radicular pain: an observational, prospective study. MOR, NRS, PR, RF
2019 Tapentadol prolonged release in fragile geriatric patients > 70 years with chronic severe musculoskeletal pain: an open-label, prospective, observational study. MOR, NRS, PR
2019 Tapentadol prolonged release in the treatment of musculoskeletal pain: an innovative pharmacological option. OA
2019 Tapentadol: an analgesic that differs from classic opioids due to its noradrenergic mechanism of action. ---
10  2018 Antidepressants versus placebo for panic disorder in adults. CCMD, CI, MAOIs, NICE, NNTB, RCTs, RR, SSRIs, TCAs
11  2018 Effects of noradrenergic and serotonergic systems on risk-based decision-making and center arena activity in open field in rats. OF, PDT, SNRI
12  2018 Tapentadol - A representative of a new class of MOR-NRI analgesics. MOR
13  2017 Acute and chronic effects of noradrenergic enhancement on transcranial direct current stimulation-induced neuroplasticity in humans. LTP, RBX, tDCS
14  2017 Atomoxetine, a norepinephrine reuptake inhibitor, reduces seizure-induced respiratory arrest. ADHD, S-IRA, SUDEP
15  2017 Dezocine exhibits antihypersensitivity activities in neuropathy through spinal mu-opioid receptor activation and norepinephrine reuptake inhibition. DORs, KORs, MOR
16  2017 Interventions for management of post-stroke depression: A Bayesian network meta-analysis of 23 randomized controlled trials. HAMD, PSD, SSRI, TCA
17  2017 Is the Noradrenergic Symptom Cluster a Valid Construct in Adjunctive Treatment of Major Depressive Disorder? CPFQ, MDD, SSRI
18  2017 Role of prefrontal cortical calcium-independent phospholipase A2 in antinociceptive effect of the norepinephrine reuptake inhibitor antidepresssant maprotiline. DHA, EPA, iPLA2
19  2017 The effect of atomoxetine, a selective norepinephrine reuptake inhibitor, on respiratory arrest and cardiorespiratory function in the DBA/1 mouse model of SUDEP. i.c.v, i.p, S-IRA, SUDEP
20  2016 Effects of escitalopram, R-citalopram, and reboxetine on serum levels of tumor necrosis factor-alpha, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration. FST, IL-10, LPS, SSRI, TNF-alpha, TST
21  2016 Is tapentadol different from classical opioids? A review of the evidence. ---
22  2016 Regulation of Calcium-Independent Phospholipase A2 Expression by Adrenoceptors and Sterol Regulatory Element Binding Protein-Potential Crosstalk Between Sterol and Glycerophospholipid Mediators. DHA, EMSA, ERK, iPLA2, MAP, SRE, SREBP
23  2016 Tapentadol: Can It Kill Two Birds with One Stone without Breaking Windows? IR, MOR
24  2015 Amelioration of deficit syndrome of schizophrenia by norepinephrine reuptake inhibitor. HAM-D, MMSE, SANS, SAS
25  2015 Chronic pain: the burden of disease and treatment innovations. MOR
26  2015 Design, synthesis and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitor. SUI
27  2015 Does tapentadol affect sex hormone concentrations differently from morphine and oxycodone? An initial assessment and possible implications for opioid-induced androgen deficiency. ER, FSH, IR, LH, OPIAD
28  2015 Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder. MDD, SSRIs
29  2015 Effects of atomoxetine on attention and impulsivity in the five-choice serial reaction time task in rats with lesions of dorsal noradrenergic ascending bundle. ADHD, DNAB, ITI, NAT
30  2015 Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: systematic review and network meta-analysis. CENTRAL, NaSSAs, rMAO-As, SARI, SNRI, SSRIs, TCAs
31  2015 Spinal neuronal correlates of tapentadol analgesia in cancer pain: a back-translational approach. MOR
32  2015 The Antidepressant Treatment Response Index as a Predictor of Reboxetine Treatment Outcome in Major Depressive Disorder. ATR, HAM-D, MDD, qEEG
33  2015 [Clinical Utility of Tapentadol]. MOR, TP
34  2014 Catechol-O-methyltransferase val158met genotype determines effect of reboxetine on emotional memory in healthy male volunteers. COMT, PFC
35  2014 Lack of synergistic interaction between the two mechanisms of action of tapentadol in gastrointestinal transit. MOR
36  2014 The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol. MOR, MOR-NRI
37  2014 The noradrenergic component in tapentadol action counteracts mu-opioid receptor-mediated adverse effects on adult neurogenesis. MOR
38  2013 Effect of tapentadol on neurons in the locus coeruleus. LC, MOR
39  2013 Efficacy and safety of noradrenalin reuptake inhibitor augmentation therapy for schizophrenia: a meta-analysis of double-blind randomized placebo-controlled trials. CIs, RR, SMD
40  2013 L-DOPA modifies the antidepressant-like effects of reboxetine and fluoxetine in rats. LC, SSRI
41  2013 Spinal-supraspinal and intrinsic mu-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice. MOR, MOR-NRI
42  2013 The effects of reboxetine treatment on depression-like behavior, brain neurotrophins, and ERK expression in rats exposed to chronic mild stress. BDNF, CMS, ERK, MWM, REB
43  2013 [Prolonged-release tapentadol for phantom pain. A case series]. MOR, VAS
44  2012 Anxiolytic-like actions of reboxetine, venlafaxine and endurance swimming in stressed male rats. BDZ, EPM, ETM, OFT, SNRI
45  2012 Different involvement of ventral and dorsal norepinephrine pathways on norepinephrine reuptake inhibitor-induced locomotion and antidepressant-like effects in rats. FST, LC, NET, PKC, RBX
46  2012 Role of prefrontal cortical calcium independent phospholipase A₂ in antidepressant-like effect of maprotiline. DHA, EPA, PFC, PUFAs
47  2012 Tapentadol increases levels of noradrenaline in the rat spinal cord as measured by in vivo microdialysis. MOR
48  2011 Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain. CFA, MOR
49  2011 Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists. ---
50  2011 Mu-opioid and noradrenergic alpha(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats. MOR
51  2011 Synergistic interaction between the two mechanisms of action of tapentadol in analgesia. MOR
52  2011 The antinociceptive and antihyperalgesic effect of tapentadol is partially retained in OPRM1 (mu-opioid receptor) knockout mice. KO, MOR
53  2011 The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects. MAOIs, MD, NDRI, SNRIs, SSRIs
54  2011 [Tapentadol: with two mechanisms of action in one molecule effective against nociceptive and neuropathic pain. Preclinical overview]. MOR
55  2010 Augmentation of the behavioural effects of desipramine by repeated immobilization stress. DMI, FST, RIS
56  2010 Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists. ---
57  2010 Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors. ---
58  2009 Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. FST
59  2009 Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template. ---
60  2009 Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists. ADHD, SERT
61  2009 Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study. NE
62  2008 Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity. ---
63  2008 Stereotypic behaviour in the deer mouse: pharmacological validation and relevance for obsessive compulsive disorder. mCPP, OCD, SRI
64  2008 The efficacy of reboxetine as an antidepressant, a meta-analysis of both continuous (mean HAM-D score) and dichotomous (response rate) outcomes. ---
65  2008 [4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors. ---
66  2007 Comparisons of glucose-insulin homeostasis following maprotiline and fluoxetine treatment in depressed males. AIR, DI, FSIGT, HAM-D, OGTT, SI
67  2007 Delivery outcome in relation to maternal use of some recently introduced antidepressants. SNRI, SSRI
68  2007 The role of noradrenergic tone in the dorsal raphe nucleus of the mouse in the acute behavioral effects of antidepressant drugs. DRN, LC, SSRIs, TST
69  2006 The effects of serotonin reuptake inhibitors on locomotor activity in gerbils. SSRIs
70  2005 Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine. HAM-D, SSRI
71  2005 Screening antidepressants in the chick separation-stress paradigm. MAOI, MAOI, SSRI, TCA
72  2003 The antidepressant efficacy of reboxetine in patients with severe depression. HAM-D
73  2002 Determination of reboxetine, a recent antidepressant drug, in human plasma by means of two high-performance liquid chromatography methods. HLB, HPLC, SPE
74  2002 Effects of reboxetine on Hamilton Depression Rating Scale factors from randomized, placebo-controlled trials in major depression. HAM-D, MDD
75  2000 Reboxetine in the treatment of bulimia nervosa: a report of seven cases. HAM-D
76  1998 Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. ---